Author(s): Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L, Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L
Abstract Share this page
Abstract This study investigated whether illness progression and treatment refractoriness emerge after relapse in schizophrenia. We compared outcomes in a cohort treated with a standardized protocol for the first and second episodes of illness. The sample comprised 31 participants who (1) had successfully completed a 2-year open-label treatment phase with risperidone long-acting injection (RLAI) for a first episode of schizophrenia; (2) underwent an intermittent treatment extension phase up to 3 years or until recurrence, and (3) entered a further 2-year treatment phase with RLAI for a recurrence episode. For the patients who remained in treatment (n = 14 [45\%]), Positive and Negative Syndrome Scale score reductions, response rates, remission rates, time to response, time to remission, functional outcome scores, and modal RLAI doses were similar for the 2 treatment periods. However, 17 (55 \%) of the 31 patients discontinued the study in the second episode compared with 14 (28\%) of 50 patients in the first episode, suggesting reduced effectiveness of antipsychotics when reintroduced after illness recurrence. Most notably, emergent treatment nonresponsiveness was observed in 5 participants (16\%), consistent with the hypothesis that relapse may be biologically harmful in a subset of patients.
This article was published in J Clin Psychopharmacol
and referenced in Journal of Neuropsychopharmacology & Mental Health